BRPI1005683A2 - processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento - Google Patents

processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento

Info

Publication number
BRPI1005683A2
BRPI1005683A2 BRPI1005683-1A BRPI1005683A BRPI1005683A2 BR PI1005683 A2 BRPI1005683 A2 BR PI1005683A2 BR PI1005683 A BRPI1005683 A BR PI1005683A BR PI1005683 A2 BRPI1005683 A2 BR PI1005683A2
Authority
BR
Brazil
Prior art keywords
dna
closed linear
kit
deoxyribonucleic acid
antigen
Prior art date
Application number
BRPI1005683-1A
Other languages
English (en)
Inventor
Hill Vanessa
Original Assignee
Touchlight Genetics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40469378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1005683(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Touchlight Genetics Limited filed Critical Touchlight Genetics Limited
Publication of BRPI1005683A2 publication Critical patent/BRPI1005683A2/pt
Publication of BRPI1005683B1 publication Critical patent/BRPI1005683B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6853Nucleic acid amplification reactions using modified primers or templates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0069Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6846Common amplification features
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y113/00Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

processo livre de células in vitro de produção de um ácido desoxirribonucleico (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento processo in vitro de produção de ácido desoxirribonucleico (dna) linear fechado compreende (a) contato de um modelo de dna que compreende pelo menos uma sequência alvo de protelomerase com pelo menos uma dna polimerase na presença de um ou mais primers sob condições que promovam a amplificação do mencionado modelo; e (b) contato de dna amplificado produzido em (a) com pelo menos uma protelomerase sob condições que promovam a formação de dna linear fechado. um kit fornece os componentes necessários no processo.
BRPI1005683-1A 2009-01-30 2010-02-01 processo in vitro, livre de células, para a produção de um ácido desoxirribonucleico (dna) linear fechado BRPI1005683B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0901593.4 2009-01-30
GBGB0901593.4A GB0901593D0 (en) 2009-01-30 2009-01-30 Production of closed linear DNA
PCT/GB2010/000165 WO2010086626A1 (en) 2009-01-30 2010-02-01 Production of closed linear dna

Publications (2)

Publication Number Publication Date
BRPI1005683A2 true BRPI1005683A2 (pt) 2019-04-02
BRPI1005683B1 BRPI1005683B1 (pt) 2019-11-12

Family

ID=40469378

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005683-1A BRPI1005683B1 (pt) 2009-01-30 2010-02-01 processo in vitro, livre de células, para a produção de um ácido desoxirribonucleico (dna) linear fechado

Country Status (20)

Country Link
US (4) US9109250B2 (pt)
EP (3) EP2391731B1 (pt)
JP (2) JP2012516147A (pt)
KR (1) KR101926662B1 (pt)
CN (2) CN104911177A (pt)
AU (1) AU2010209532B2 (pt)
BR (1) BRPI1005683B1 (pt)
CA (1) CA2751130C (pt)
DK (2) DK2391731T3 (pt)
EA (1) EA021069B1 (pt)
ES (2) ES2400890T3 (pt)
GB (1) GB0901593D0 (pt)
HK (1) HK1159693A1 (pt)
IL (1) IL213930A (pt)
LT (1) LT3150722T (pt)
MX (1) MX2011007937A (pt)
NZ (1) NZ594004A (pt)
SG (1) SG173102A1 (pt)
WO (1) WO2010086626A1 (pt)
ZA (1) ZA201105013B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351294B8 (es) * 2009-07-02 2012-06-06 Consejo Superior De Investigaciones Científicas (Csic) Metodo para la replicación, amplificación, o secuenciación de un adn molde.
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9290800B2 (en) 2013-03-15 2016-03-22 Pacific Biosciences Of California, Inc. Targeted rolling circle amplification
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
CN107614675B (zh) * 2015-07-16 2021-08-17 香港科技大学 用于单分子dna分析的纳米通道的动态形成
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
RU2616279C1 (ru) * 2015-12-28 2017-04-13 Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) Способ получения маркерных лестниц для гель-электрофоретического определения размеров фрагментов нуклеиновых кислот
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
WO2018033730A1 (en) 2016-08-16 2018-02-22 Touchlight IP Limited Closed linear dna production
TW201936201A (zh) 2017-12-14 2019-09-16 美商堅固生物科技公司 基因之非病毒生產及遞送
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
CN109971825B (zh) * 2017-12-28 2020-11-10 南京金斯瑞生物科技有限公司 快速制备桑格测序模板的方法
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
JP2021528959A (ja) * 2018-06-22 2021-10-28 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 細胞内で存続する遺伝子送達のためのベクター
EP3873537A4 (en) * 2018-11-02 2022-10-12 Nikegen Limited RECOMBINANT PARVOVIRUS VECTORS AND METHODS FOR THEIR PRODUCTION AND USE
CA3141323A1 (en) 2019-06-18 2020-12-24 Helen Horton Recombinant interleukin 12 construct and uses thereof
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
KR20220041080A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
WO2020255009A2 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
WO2020255008A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
EP3986562A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
EP3986457A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
CA3143631A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
EP3792367A1 (en) 2019-09-11 2021-03-17 Universität Bielefeld Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest
AU2020351204A1 (en) 2019-09-18 2022-04-21 Aldevron, Llc Synthetic DNA vectors and methods of use
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
AU2020407850A1 (en) 2019-12-20 2022-06-30 Keygene N.V. NGS library preparation using covalently closed nucleic acid molecule ends
CA3162520A1 (en) * 2020-01-17 2021-07-22 Jacob Smith Recombinant aav production
GB202007428D0 (en) 2020-05-19 2020-07-01 Fabricnano Ltd Polynucleotide synthesis
CN116133668A (zh) 2020-06-12 2023-05-16 罗切斯特大学 ACE-tRNA的编码和表达
BR112023002195A2 (pt) 2020-08-26 2023-03-14 Scancell Ltd Ácido nucleico que codifica um polipeptídeo, vetor, peptídeo, e composição de vacina
WO2022074058A1 (en) 2020-10-06 2022-04-14 Keygene N.V. Targeted sequence addition
EP4317424A1 (en) 2021-03-29 2024-02-07 Kaneka Corporation Vector, method for preparing linear covalent bond closed dna using same, parvovirus vector preparation method, and parvovirus vector producing cell
JP2024520797A (ja) 2021-06-08 2024-05-24 タッチライト・アイピー・リミテッド レンチウイルスベクター
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
WO2022272297A1 (en) 2021-06-25 2022-12-29 Oxford Biomedica Solutions Llc Adeno-associated virus packaging systems
WO2023285976A1 (en) 2021-07-13 2023-01-19 Stonehaven Incubate AG Composition and uses thereof
ES2947031T6 (pt) * 2021-07-30 2023-08-02
GB202114105D0 (en) 2021-10-01 2021-11-17 Fabricnano Ltd Nucleotide synthesis
US20230279433A1 (en) 2021-12-15 2023-09-07 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023122303A2 (en) * 2021-12-23 2023-06-29 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
CN114561372B (zh) * 2022-04-27 2022-07-26 南京巨匠生物科技有限公司 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
WO2024032690A1 (zh) * 2022-08-10 2024-02-15 江苏金斯瑞蓬勃生物科技有限公司 线性闭合dna的制备方法及该方法所用质粒
WO2024069549A1 (en) 2022-09-29 2024-04-04 Touchlight Aquaculture Limited Vaccine construct and uses thereof
WO2024094793A1 (en) 2022-11-02 2024-05-10 4Basebio, S.L.U. Purification of linear dna products
EP4365303A1 (en) 2022-11-02 2024-05-08 4basebio, S.L.U. Purification of linear dna products
WO2024121354A1 (en) 2022-12-08 2024-06-13 Keygene N.V. Duplex sequencing with covalently closed dna ends
CN116606834A (zh) * 2023-04-10 2023-08-18 天津中合基因科技有限公司 多种具有切割连接活性的原端酶及其应用
US11981936B1 (en) 2023-09-29 2024-05-14 New England Biolabs, Inc. TelA variants, compositions, and methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン,インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US6953676B1 (en) 1992-05-01 2005-10-11 Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification device and method
WO1994003624A1 (en) 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
EP0636413B1 (en) 1993-07-28 2001-11-14 PE Corporation (NY) Nucleic acid amplification reaction apparatus and method
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
WO1997019193A2 (en) 1995-11-21 1997-05-29 Yale University Unimolecular segment amplification and detection
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
JPH10234399A (ja) 1997-02-28 1998-09-08 Shinkinrui Kinou Kaihatsu Kenkyusho:Kk ピシウム属菌検出用の核酸配列
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6054274A (en) * 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
DK1179585T3 (da) 1997-12-24 2008-11-10 Cepheid Indretning og fremgangsmåde til lysis
DE69934088T2 (de) 1998-01-09 2007-06-21 University Of Utah Research Foundation, Salt Lake City Verfahren zur in vitro amplifikation zirkulärer dna
DE19826758C1 (de) 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
WO2000015779A2 (en) 1998-09-15 2000-03-23 Yale University Molecular cloning using rolling circle amplification
DE50010240D1 (de) * 1999-07-08 2005-06-09 Mologen Forschungs Entwicklung Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
WO2001077384A2 (de) 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
GB0018120D0 (en) 2000-07-24 2000-09-13 Fermentas Ab Nuclease
US6977148B2 (en) 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US20030077611A1 (en) 2001-10-24 2003-04-24 Sention Methods and systems for dynamic gene expression profiling
CA2412187A1 (en) 2001-12-21 2003-06-21 University Of Western Ontario Assay for identifying modulators of borrelia telomere resolvase
US7081339B2 (en) 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
WO2004007684A2 (en) 2002-07-12 2004-01-22 Affymetrix, Inc. Synthetic tag genes
US20040022764A1 (en) 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
ES2270120T3 (es) * 2002-09-23 2007-04-01 Mologen Ag Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina.
US7955795B2 (en) 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
WO2004065582A2 (en) 2003-01-15 2004-08-05 Dana-Farber Cancer Institute, Inc. Amplification of dna in a hairpin structure, and applications
DE602004021235D1 (de) 2003-02-21 2009-07-09 Geneform Technologies Ltd Verfahren, kits und reagenzien zur nukleinsäuresequenzierung
WO2005054435A2 (en) 2003-11-26 2005-06-16 Eppendorf Ag Methods and compositions for in vitro amplification of extrachromosomal nucleic acid
WO2006063355A2 (en) 2004-12-11 2006-06-15 Cytogenix , Inc. Cell free biosynthesis of high-quality nucleic acid and uses thereof
EP1871897B1 (en) 2005-04-12 2010-09-29 Olink AB Methods for production of oligonucleotides
BRPI0607661A2 (pt) 2005-04-29 2009-09-22 J Craig Venter Inst amplificação e clonagem de molécula de único dna usando amplificação de cìrculo rolante
US8093030B2 (en) 2005-10-06 2012-01-10 Lucigen Corporation Thermostable viral polymerases and methods of use
EP1974037B1 (en) * 2006-01-12 2012-03-14 Lucigen Corporation Linear vectors, host cells and cloning methods
CA2713101C (en) 2006-10-06 2016-09-13 Vandalia Research, Inc. Method for a continuous rapid thermal cycle system
US9598724B2 (en) * 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8921072B2 (en) 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9114399B2 (en) 2010-08-31 2015-08-25 Canon U.S. Life Sciences, Inc. System and method for serial processing of multiple nucleic acid assays
EP2692870A1 (en) 2012-08-03 2014-02-05 Alacris Theranostics GmbH Method for nucleic acid amplification
KR102014989B1 (ko) 2013-04-15 2019-08-27 삼성전자주식회사 폴리뉴클레오티드 및 그의 용도

Also Published As

Publication number Publication date
JP2012516147A (ja) 2012-07-19
DK2391731T3 (da) 2013-04-22
BRPI1005683B1 (pt) 2019-11-12
KR101926662B1 (ko) 2018-12-07
EP3150722A1 (en) 2017-04-05
GB0901593D0 (en) 2009-03-11
JP6454243B2 (ja) 2019-01-16
NZ594004A (en) 2013-01-25
CA2751130C (en) 2018-03-06
EP2612925A1 (en) 2013-07-10
EP2612925B1 (en) 2016-11-30
AU2010209532B2 (en) 2015-06-25
ES2749629T3 (es) 2020-03-23
DK3150722T3 (da) 2019-12-16
US20150329902A1 (en) 2015-11-19
SG173102A1 (en) 2011-08-29
EA021069B1 (ru) 2015-03-31
EP2391731B1 (en) 2013-01-23
WO2010086626A1 (en) 2010-08-05
US9109250B2 (en) 2015-08-18
KR20110107846A (ko) 2011-10-04
EA201101141A1 (ru) 2012-05-30
IL213930A0 (en) 2011-07-31
AU2010209532A1 (en) 2011-07-28
HK1159693A1 (en) 2012-08-03
CN104911177A (zh) 2015-09-16
US20120282283A1 (en) 2012-11-08
CN102301010A (zh) 2011-12-28
LT3150722T (lt) 2019-12-10
US20220372565A1 (en) 2022-11-24
CA2751130A1 (en) 2010-08-05
EP3150722B1 (en) 2019-09-11
US20190203282A1 (en) 2019-07-04
JP2016047049A (ja) 2016-04-07
US11384388B2 (en) 2022-07-12
IL213930A (en) 2014-08-31
MX2011007937A (es) 2011-08-17
CN102301010B (zh) 2015-07-08
ES2400890T3 (es) 2013-04-15
ZA201105013B (en) 2013-03-27
EP2391731A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
BRPI1005683A2 (pt) processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento
Li et al. Homocysteine triggers inflammatory responses in macrophages through inhibiting CSE-H2S signaling via DNA hypermethylation of CSE promoter
BR112022003089A2 (pt) Métodos de produção de células progenitoras hemogênicas a partir de células-tronco pluripotentes
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
BRPI0611535A8 (pt) Métodos para processar células de microorganismos e células de levedura, composição, suplemento alimentar, produto farmacêutico, cosmético ou produto nutracêutico e ração animal
BR112016005228A8 (pt) Uso de uma ou mais glicosidases e processo para produzir um oligossacarídeo
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
BRPI0712171A8 (pt) Método para formatar um gráfico e sistema para modificar um gráfico
BR112015030918A2 (pt) método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
BR112013031021A2 (pt) composições e métodos para a inibição da expressão de gene do vírus da hepatite b'
BRPI0802049A2 (pt) composiÇço cosmÉtica ou dermatolàgica, usos de pelo menos um meio de cultura celular, processo cosmÉtico para melhorar a homeostase cutÂnea e processo para preparar uma composiÇço cosmÉtica ou dermatolàgica
BR112013010186B8 (pt) Cerâmicas vítreas de silicato de lítio ou, seu uso e seu método de produção, e produto odontológico formatado
BR112013030958A2 (pt) "anticorpo que se liga ao fator de transformação de crescimento beta e seu uso no tratamento de câncer, fibrose e doenças associadas com expressão do referido fator, bem como molécula de ácido nucleico, vetor de expressão, célula hospedeira e seu método de uso para produzir anticorpo e composição farmacêutica".
AR053552A1 (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
BRPI0508704A (pt) métodos para a preparação de um composto e para a preparação de calcipotriol ou monoidrato de calcipotriol, composto, e, usos de um composto e de éster dietìlico do ácido (2-ciclopropil-2-oxoetil) fosfÈnico
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
BR112012015119A2 (pt) "ácidos graxos de cadeia ramificada e produção biológica dos mesmos".
BR112016023823A2 (pt) método para produção de um produto de fermentação
BRPI0818718B8 (pt) processo de preparo de uma composição de vacina compreendendo antígeno e adjuvante na forma de látex inverso de homopolímero do ácido acrílico
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
Marsico et al. Unraveling the consequences of oxygen imbalance on early embryo development: Exploring mitigation strategies
BRPI0520568A2 (pt) uso de esqueleto de parede celular de nocardia rubra na preparação de medicamentos para infecção anti-hpv
Yi et al. Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP prostate cancer cells

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2519 DE 16/04/2019 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2010, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: TOUCHLIGHT IP LIMITED (GB)